National Bank of Canada FI Has $9.50 Million Stock Holdings in STERIS plc (NYSE:STE)

National Bank of Canada FI grew its stake in STERIS plc (NYSE:STE - Free Report) by 16.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,221 shares of the medical equipment provider's stock after purchasing an additional 6,486 shares during the quarter. National Bank of Canada FI's holdings in STERIS were worth $9,501,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of STE. Avalon Trust Co acquired a new position in STERIS during the 4th quarter valued at about $30,000. Human Investing LLC purchased a new position in shares of STERIS in the fourth quarter worth approximately $31,000. Anfield Capital Management LLC boosted its stake in STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 91 shares during the period. Central Pacific Bank Trust Division grew its position in STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 76 shares in the last quarter. Finally, Manchester Capital Management LLC raised its stake in STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 137 shares during the period. 94.69% of the stock is owned by institutional investors.

Analyst Ratings Changes

STE has been the subject of several research analyst reports. Stephens reissued an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler boosted their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research report on Monday. Finally, JMP Securities reiterated a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a report on Thursday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $258.75.

Remove Ads

STERIS Stock Down 3.5 %

Shares of NYSE:STE traded down $7.85 on Thursday, reaching $215.09. The company had a trading volume of 175,840 shares, compared to its average volume of 535,401. The stock has a 50-day moving average price of $222.60 and a 200 day moving average price of $219.88. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The stock has a market capitalization of $21.13 billion, a P/E ratio of 45.72 and a beta of 0.87.

STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, equities analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 21st. Stockholders of record on Thursday, February 20th were issued a dividend of $0.57 per share. The ex-dividend date was Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.06%. STERIS's dividend payout ratio (DPR) is presently 48.41%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.